The study evaluates CX-5461 as a monotherapy in a heavily pretreated population, including individuals with pancreatic, breast, and ovarian cancers who have undergone a median of six prior lines of therapy. Many of these participants have already exhausted standard options, including PARP inhibitors, creating an urgent demand for alternative therapeutic pathways. With the trial now closed to new entries, the company has shifted its focus to database reconciliation and comprehensive statistical analysis, with a final Clinical Study Report anticipated in the first quarter of 2027.

Preliminary data shared at the 2026 ASCO Annual Meeting highlighted the drug’s potential, showing a 60% disease control rate in a cohort of ovarian cancer patients who had previously failed PARP inhibitor treatments. Because CX-5461 utilizes a mechanism distinct from traditional PARP inhibition, Senhwa aims to position the drug as a vital option for overcoming resistance in precision oncology. These upcoming results will dictate the company’s strategy for indication prioritization and potential future combinations with immunotherapies or antibody-drug conjugates.